Trial Profile
A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Sep 2023
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- Sponsors GSK
- 06 Jan 2012 Actual patient number is 109 according to ClinicalTrials.gov.
- 06 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.